KOR Life Sciences

KOR Life Sciences is a private U.S. drug discovery company based in Charleston, South Carolina, focused on oncology and other complex diseases. The company describes itself as a collaborative research organization developing therapeutics, diagnostics, and personalized medicine approaches, with an emphasis on novel small molecules and nanoparticle-enabled delivery systems. Its disclosed pipeline is primarily preclinical and includes QD502, an orally bioavailable quinazoline-based small molecule for oncology, as well as programs in glioblastoma, pancreatic cancer, and calcific aortic valve disease. KOR also highlights proprietary Up-Conversion Nanoparticles for brain tumor applications and research into DDX3 inhibition and metformin-based anticancer compounds. Public materials indicate the company was established in 2019 and has operated as a subsidiary or research division associated with Vikor Scientific.